← Leaderboards
Nilu Goonetilleke
Univ Of North Carolina Chapel Hill
$10,203,419
Attributed
$10,203,419
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2017–23$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,203,419 · 2
By mechanism
U01$7,243,525 · 1
U19$2,959,894 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Toni Darville$28,754,279
- Joseph A Duncan$15,933,718
- Cesar Augusto Lopez$158,016
- Sarah E. Rutstein$2,699,732
- Ashley Grace Polson$36,856
Others in their field
Other Emerging Leaders on “Vaccines”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$149,372,007
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$74,099,786
- Ted Ross · University Of Georgia$71,962,304
Research focus
VaccinesSafetyProteinsVaccine EvaluationVirusT-LymphocyteImmunogenicModified Vaccinia Virus AnkaraStandardizationVaccinationVectorViral VectorFrequenciesUniversitiesClinical TrialsCd4 Positive T LymphocytesCd8-Positive T-LymphocytesAntigensRegimenGenetic TranscriptionGenerationsGrantEpitopesAmerican
Grant awards (12)
Chlamydial Vaccine Testing in Mice and Guinea Pigs$695,230
U19 · FY2023 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$570,647
U01 · FY2023 · AI · contact PI
Chlamydial Vaccine Testing in Mice and Guinea Pigs$705,162
U19 · FY2022 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$594,846
U01 · FY2022 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$1,411,211
U01 · FY2021 · AI · contact PI
Chlamydial Vaccine Testing in Mice and Guinea Pigs$533,605
U19 · FY2021 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$1,279,617
U01 · FY2020 · AI · contact PI
Chlamydial Vaccine Testing in Mice and Guinea Pigs$481,931
U19 · FY2020 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$1,205,048
U01 · FY2019 · AI · contact PI
Chlamydial Vaccine Testing in Mice and Guinea Pigs$543,966
U19 · FY2019 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$1,169,548
U01 · FY2018 · AI · contact PI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1$1,012,608
U01 · FY2017 · AI · contact PI